Results 41 to 50 of about 21,080,479 (286)

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

, 2019
B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease.
Saiko Kurosawa, Katsuaki Imaizumi, Shinichi Makita, Kensei Tobinai   +3 more
core   +1 more source

Nephrotoxicity in CAR-T Cell Therapy

Transplantation and Cellular Therapy
Chimeric antigen receptor (CAR)-T cell therapy is a novel therapy for the treatment of different hematologic malignancies. Besides its efficiency, CAR-T cell therapy is associated with significant toxicity, primarily manifested as cytokine release syndrome (CRS) and neurotoxicity.
Karol Sadowski, Weronika Ploch, Alicja Downar, Wiktoria Giza, Dorota Szcześ, Wioletta Olejarz, Wiesław W. Jędrzejczak, Jolanta Małyszko, Grzegorz Basak   +8 more
openaire   +2 more sources

Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia

Journal for ImmunoTherapy of Cancer, 2023
The treatment of B cell malignancies has dramatically changed with the introduction of immunotherapy, especially chimeric antigen receptor T (CAR-T) cell therapy. However, only limited efficacy is observed in acute myeloid leukaemia (AML).
Ting Yang, Jingjing Wen, Yanxin Chen, Jiajie Yang, Chunye Dai, Shenjie Yu, Wenting Zhong, Lilin Liu, Chengguanng He, Wenmin Zhang, Lingfeng Liu, Jianda Hu   +11 more
doaj   +1 more source

Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies

, 2023
Chimeric-antigen-receptor (CAR) T-cell therapy for CD19-expressing B-cell malignancies is already widely adopted in clinical practice. On the other hand, the development of CAR-T-cell therapy for T-cell malignancies is in its nascent stage.
Chikao Morimoto, Nam H. Dang, Taketo Yamada, Tsutomu Sato, Akinori Wada, Yoshihiro Hayakawa, Ryo Hatano, Tatsuhiko Ozawa, Takeshi Susukida, Eiji Kobayashi, Miho Arai, Shohei Kikuchi, Yuichi Adachi, Hiroyuki Kishi, Noriaki Iwao, Yusuke Kamihara   +15 more
core   +1 more source

CAR T-Cell Therapy: Progress and Prospects

, 2017
Lentivirus-mediated transduction of autologous T cells with a chimeric antigen receptor (CAR) to confer a desired epitope specificity as a targeted immunotherapy for cancer has been among the first human gene therapy techniques to demonstrate widespread ...
Flotte, Terence R., Wilkins, Olivia, Keeler, Allison M   +2 more
core   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Bystander CAR−CD8+ T cells in a CAR-T cell product can expand and enhance the antitumor effects of a bispecific antibody

Journal for ImmunoTherapy of Cancer
Although bispecific antibody (BsAb) treatment is a valuable therapeutic option for post chimeric antigen receptor (CAR)-T cell therapy against relapsed/refractory large B-cell lymphoma, it remains to be clarified why it is still effective after intensive
Toshiki Ochi, Tatsuya Konishi, Jun Yamanouchi, Takatsugu Honda, Katsuto Takenaka, Junichi Kato, Masaki Maruta, Shogo Nabe, Yuya Masuda, Meika Matsumoto, Natsumi Kawasaki, Yukihiro Miyazaki, Yasukazu Doi, Yasunori Takasuka   +13 more
doaj   +1 more source

The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies

ImmunoMedicine, 2022
Chimeric antigen receptors (CAR) T‐cell therapy is one of the most effective treatments in curing hematologic malignancies. Besides the four CD19 CAR T‐cells therapy recently approved by the US Food and Drug Administration (FDA), CD20 CAR T‐cell therapy ...
Elaine Tan Su Yin, Yong Xian Hu, He Huang   +2 more
doaj   +1 more source

Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies

Chinese Medical Journal, 2023
. Cellular therapies have revolutionized the treatment of hematological malignancies since their conception and rapid development. Chimeric antigen receptor (CAR)-T cell therapy is the most widely applied cellular therapy.
Zhihuan Yang, Ying Wang, Peifang Wei
doaj   +1 more source

Characterization of the effect of T cell killing ability and resistance to environmental ROS on the efficiency of CAR-T cell Immunotherapy

, 2023
reservedChimeric Antigens Receptor (CAR) T cells adoptive transfer represents a revolutionary strategy in cancer treatment. Indeed, anti-CD19 CAR T cells therapy has dramatically changed the fate of patients with relapsed/refractory (r/r)diffuse large ...
DARBAN, HANIEH
core